AlzeCure highlighted in a report on Parkinson’s and Alzheimer’s

A new report from Invest Stockholm conducts a review of knowledge about neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Both the region’s academic research and selected companies are presented here.

The report highlights one of Flemingsberg’s knowledge companies: AlzeCure. Here, the company’s CEO Martin Jönsson talks about the development of new treatments for Alzheimer’s disease.

It is estimated that the number of people with dementia will increase from 50 million today to 150 million in 2050. Alzheimer’s disease is the most common form of dementia and is a major cause of disability and dependency among old people worldwide. Parkinson’s disease is the second most common age-related neurodegenerative disorder and can also have a devastating impact on quality of life.

Universities and research institutes in the greater Stockholm region are carrying out vital research into these diseases, which will help to achieve early diagnosis and reduce the impact of neurodegenerative conditions on people’s lives.

Read the new report from Invest Stockholm: Improving Quality of Life for People with Neurodegenerative Diseases

Photo: Anna Hugosson, mediabank.visitstockholm.com

“Soon we can meet again IRL”

Since the Covid outbreak, our work has been characterised by video meetings, especially in our various focus groups. Success has exceeded expectations, thanks to the fact that the approximately 70 people who are involved in the groups had time to get to know one other and the issues even before the pandemic. But we are really looking forward to being able to meet again IRL, and hopefully soon – it is so much more enjoyable!

XNK Therapeutics lays the groundwork for GMP facility in Flemingsberg

"Flemingsberg is the place in the world you want to be if you work with NK cells. There is a strong research facility here with a world-leading research group and proximity to a clinic that really knows NK cells. We recently started the construction of a new GMP facility with an associated research laboratory of 350 square meters for our NK cell therapy. The new facility is being built at Novum in Flemingsberg and, once the facility is completed in 2022, it will give us complete control over the entire development chain."

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

PRENUMERERA

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

PRENUMERERA
CF_logo_neg
2021-02-09T16:36:09+01:00
Go to Top